Close Menu

NEW YORK (GenomeWeb) – Meridian Bioscience announced today that its preliminary fiscal second quarter revenues are expected to be down nearly 12 percent year over year driven by a decline in revenues in its diagnostics segment.

For fiscal Q2 2019, the company said that revenues are anticipated to be approximately $50.0 million compared to $56.5 million a year ago. The analysts' average estimate is $56.4 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.